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Supplementary Table 1: Characteristics of studies from the TenoRes collaboration included in the present analysis 
Study 
 
 
        Country 
 
 
Income 
region 
 
 
Study 
type 
Underlying 
cohort 
exclusively 
first line 
treated? 
 
Follow-up 
Active* or  
passive 
 
 
 
N 
 
TDF 
resistanc
e 
 
VL 
threshold 
for 
genotype 
 
Use of  
FTC 
 
Use of 
NVP 
 
Baselin
e  
CD4 
<100 
 
Baseline 
viral 
load 
>100,000 
 
Sub Saharan Africa 
 
ACTION Nigeria LMIC Cohort Yes Passive 17 10  1000 17 (100%) 7 (41%) 
10 
(59%) - 
ACTION Plus UP, Nigeria LMIC Cohort Yes Passive 21 17  1000 18 (86%) 12 (57%) 8 (38%) - 
Doris Duke Study Nigeria LMIC Trial Yes Active 13 8 1000 0 (0%) 3 (23%) 5 (38%) 7 (54%) 
Harvard/APIN PEPFAR Nigeria LMIC Cohort No Active 20 15 2000 18 (90%) 19 (95%) 16 (80%) 17 (85%) 
CDC Nigeria ADR Nigeria LMIC Cohort Yes Passive 6 3 1000 5 (83%) 6 (100%) 2 (33%) 4 (67%) 
Lubumbashi, DRC LIC Trial Yes Active 12 6 1000 12 (100%) 12 (100%) 7 (58%) 9 (75%) 
UVRI/MoH Uganda 
surveillance study Uganda LIC Cohort Yes Passive 35 19 1000 18 (51%) 24 (69%) 
18 
(51%) 29 (83%) 
CDC Uganda ADR Uganda LIC Cohort Yes Passive 5 3 1000 4 (80%) 3 (60%) 2 (40%) - 
CDC/MoH, Tanzania Tanzania LIC Cohort No Active 15 3 1000 12 (80%) 1 (7%) - - 
CDC Kenya ADR Kenya LMIC Cohort Yes Passive 43 31 1000 1 (2%) 27 (63%) 17 (40%) - 
TDF AMPATH Kenya LMIC Cohort Yes Active 27 19 1000 0 (0%) 23 (85%) - - 
PASER 
Nigeria, Uganda, 
South Africa, 
Kenya, Zambia, 
Zimbabwe 
LMIC Cohort No Active 53 19 1000 52 (98%) 17 (32%) 27 (51%) 35 (66%) 
Aurum, KZN South Africa HMIC Cohort No Active 11 0 1000 9 (82%) 3 (27%) 1 (9%) 0 (0%) 
Africa Centre, KZN South Africa HMIC Cohort No Passive 64 45 1000 0 (0%) 10 (16%) 32 (50%) - 
Bloemfontein, South Africa HMIC Cohort No Passive 78 59 1000 2 (3%) 16 (21%) 14 (18%) 1 (1%) 
RFVF, Durban South Africa HMIC Cohort Yes Passive 51 34 1000 0 (0%) 7 (14%) 26 (51%) 0 (0%) 
CDC/NCID, KZN, South Africa HMIC Cohort Yes  98 49 1000 0 (0%) 33 (34%) - - 
MSF Swaziland HMIC Cohort No Active 22 12 1000 0 (0%) 5 (23%) 10 (45%) 6 (27%) 
CDC Zambia ADR Zambia LMIC Cohort No Passive 14 8 1000 13 (93%) 1 (7%) 4 (29%) - 
OCTANE 
Kenya, Botswana, 
Malawi, South 
Africa, Zambia, 
Zimbabwe 
LMIC Trial Yes Active 36 7 2000 36 (100%) 36 (100%) 
16 
(44%) 27 (75%) 
Supplementary Table 2: Number of patients with available data for covariates and number of patients contributing to subgroup analyses. 
Study N N with 
information 
on CD4 or 
viral load 
 Patients contributing to subgroup analyses 
     NRTI  Gender  NNRTI  Baseline CD4  
(cells/mm3) 
 Viral load (log10 HIV1-
RNA/ml) 
  Base
- 
line 
CD4 
Base-
line 
viral 
load 
 3TC FTC  Female Male  EFV NVP  Unavail- 
able 
<100 >100  Unavai- 
lable 
<5 >5 
Eastern Africa 159 108 57  38 104  76 62  98 42  36 55 53  87 8 48 
CDC Kenya ADR 56 51 0  0 55  36 20  36 20  5 24 27  56 0 0 
CDC/MoH, Tanzania 15 0 0  0 0  0 0  0 0  0 0 0  0 0 0 
PASER Uganda 16 16 16  15 0  0 10  6 10  0 9 7  0 0 15 
TDF AMPATH, Kenya 31 0 0  0 31  18 13  27 0  31 0 0  31 0 0 
UVRI/MoH Uganda 
surveillance study 
41 41 41  23 18  22 19  29 12  0 22 19  0 8 33 
Southern Africa 461 248 101  58 379  266 146  82 333  198 109 96  356 38 22 
Africa Centre, South 
Africa 
81 71 0  0 81  62 19  0 70  0 42 29  81 0 0 
Aurum, South Africa 12 11 11  0 0  0 0  0 0  0 0 0  0 0 0 
Bloemfontein, South 
Africa 
102 26 5  3 99  62 40  19 83  76 18 8  97 0 0 
CDC Zambia ADR 17 14 0  16 0  11 6  3 14  0 0 10  17 0 0 
Durban, South Africa 58 51 12  0 58  25 33  0 51  7 29 22  46 12 0 
KZN, South Africa 115 0 0  0 115  64 38  38 77  115 0 0  115 0 0 
MSF Swaziland 26 26 25  0 26  16 10  6 20  0 13 13  0 17 8 
OCTANE South Africa 16 16 16  16 0  16 0  16 0  0 7 0  0 0 14 
PASER South Africa 11 10 11  0 0  0 0  0 0  0 0 0  0 0 0 
PASER Zambia 23 23 21  23 0  10 0  0 18  0 0 14  0 9 0 
West/Central Africa 92 89 50  56 13  27 33  50 20  0 37 20  21 12 29 
ACTION Plus UP, Nigeria 21 20 0  0 0  0 0  0 0  0 0 0  0 0 0 
ACTION, Nigeria 21 19 0  21 0  0 15  10 11  0 14 0  21 0 0 
Lubumbashi, DRC 13 13 13  13 0  8 0  13   0 0 6  0 0 10 
    Doris Duke study,  13 13 13  0 13  7 6  4 9  0 5 8  0 7 0 
Nigeria, Kanki 24 24 24  22 0  12 12  23 0  0 18 6  0 5 19 
 
 Supplementary Table 3: Information on drug resistance and baseline characteristics of participants by HIV-1 subtype. Note that subtype 
AG is also known as CRF_02 
 
Subtype N TAM, N (%)  TDF 
resistance, N 
(%) 
EFV or NVP 
resistance, 
N(%) 
Lamivudine 
resistance, 
N(%) 
NVP use,  
N(%) 
FTC use, N(%) Baseline CD4 (cells/mm3), 
median (IQR) 
Baseline viral load 
(log10/ml), 
median (IQR) 
A 90 21 (23.3%) 52 (57.8%) 73 (81.1%) 60 (66.7%) 65 (72.2%) 25 (27.8%) 113.0 (50.0 to 223.0) 5.6 (5.2 to 5.9) 
AG/G 49 10 (20.4%) 38 (77.6%) 46 (93.9%) 44 (89.8%) 33 (67.3%) 37 (75.5%) 66.0 (30.0 to 126.0) 5.2 (4.7 to 5.5) 
C 481 80 (16.6%) 293 (60.9%) 404 (84.0%) 305 (63.4%) 122 (25.4%) 87 (18.1%) 93.5 (34.0 to 159.0) 4.8 (3.6 to 5.5) 
D 42 3 (7.1%) 30 (71.4%) 30 (71.4%) 31 (73.8%) 22 (52.4%) 23 (54.8%) 77.0 (25.5 to 178.5) 5.6 (5.0 to 5.8) 
Other 50 1 (2.0%) 32 (64.0%) 42 (84.0%) 38 (76.0%) 28 (56.0%) 32 (64.0%) 92.0 (26.0 to 221.0) 5.4 (5.1 to 5.9) 
 
 
 
Supplementary Figure 1: a) Scatter of study-level prevalence of NNRTI resistance and prevalence of TAM by region. Markers are 
weighted by study size. (Spearman’s rho=0.62 p<0.0001);  b) meta-analysis of odds ratios for NNRTI resistance in participants with 
TAM versus those without TAM within individual studies  
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Supplementary Figure 2: a) Scatter of study-level prevalence of lamivudine resistance and prevalence of TAM by region. Markers 
are weighted by study size. (Spearman’s rho=0.65 p<0.0001;  b) meta-analysis of odds ratios for lamivudine resistance in participants 
with TAM versus those without TAM within individual studies  
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 Supplementary Figure 3: Estimated prevalence of drug resistant mutations, sensitivity analyses including all participants from studies 
in sub-Saharan Africa (including those with <10 patients) 
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Supplementary Figure 4: Within study comparison of tenofovir resistance by presence or absence of TAMs; sensitivity analyses 
including all participants from studies in sub-Saharan Africa (including those with <10 patients) 
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Study Groups  
Uganda Virus Research Institute/Ministry of Health (UVRI/MoH) Uganda surveillance study: Fred Lyagoba, Tom Lutalo
,
, Anne, 
Kapaata, Faith Nanyonga, Chris Parry, Norah Namuwenge, Robert Downing, The HIV Drug Resistance Working group and 
participants and study teams from the treatment centers at Masaka and Mbale regional referral hospitals and Nsambya Home-Care.  
 
 ACTG 5208 study team: Shahin Lockman, John Mellors, Michael Hughes, Fred Sawe, James McIntyre, Judy Currier. Research 
reported in this publication was supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of 
Health under Award Number UM1 AI068634, UM1 AI068636 and UM1 AI106701. The content is solely the responsibility of the 
authors and does not necessarily represent the official views of the National Institutes of Health 
 
RFVF: We would like to express our deepest admiration and appreciation for the patients who participated in the study and the work 
of the Sinikithemba Clinic at McCord Hospital in Durban, South Africa for their commitment to improve patient care and support 
research. The tremendous contributions on the part of the counselors, medical records staff, nurses, and medical officers have been 
essential to the success of this study. Sabelo Dladla, Michelle Gordon, Jane Hampton, Brent Johnson, Daniel Kuritzkes, Roma 
Maharaj, Darius McDaniel, Kristy Nixon, Claudia Ordonez, Melisha Pertab and Sifiso Shange provided vital assistance for the data 
collection and analysis. 
  
Tanzanian, Kenyan and Ugandan Ministries of Health 
 The Harvard/AIDS Prevention Initiative in Nigeria (APIN) prevention, treatment and care program: Participating hospitals in this 
study included the University College Hospital, University of Ibadan, Ibadan, Lagos University Teaching Hospital, University of 
Lagos, Lagos, Jos University Teaching Hospital, University of Jos, and the Nigerian Institute of Medical Research, Lagos.  
 
PEPFAR and CDC  
Tanzanian, Nigeria and Kenyan Ministries of Health. Infectious Disease Institute, Uganda and Tropical Disease Research Centre, 
Zambia.  
The Cross Sectional Survey of Acquired Drug Resistance Study at Sentinel Sites Study Team: 
University of Maryland: Robert Redfield, Sekela Mwakyusa, Peter Memiah, Martine Etienne-Mesubi, Sandra Medina-Moreno, 
Andrew Kigombola, Sylvia Ojoo, Francesca Odhiambo,  
Westat: Karen Megazzini, Annie Lo, Laura Alvarz-Rojas 
Kenya: Sarah Masyuko, Shobha Vakil, Ibrahim Mohammed, David Kimanga, Maureen Kimani, and the Kenya National HIVDR 
working group 
Tanzania/Zanzibar: Bonita Kilama, Mathias Abuya, Ben Rabiel, Sophia Mohamed, Jullu Boniphace, Geoffrey Somi, Ahmed Khatibu 
and the Tanzanian National HIVDR working group 
CDC-Kenya: Lucy Nganga, Evelyn Ngugi, Andrea Kim, Jane Mwangi, Anthony Gichangi, Abraham Kitana, Frankline Onchiri, 
Frederick Miruka 
CDC-Tanzania: Mary Kibona, Julius Muhumuza, Jennifer Ward, John Rogers, Duncan Donnay, Rama Mwiru, Godwin Munuo, 
Mohamed Mfaume, Eunice Mmari, Michelle Roland. 
CDC-Atlanta: Tedd Ellerbrock, Laura Broyles, Jennifer Sabatier, Emilia Rivadeneira, Guoqing Zhang, Joshua R. DeVos, Nicolas 
Wager, Duping Zheng, Karidia Diallo and R. Suzanne Beard. 
 
We would like to thank the following members of the TenoRes study team: Lou Halvas, Lameck Diero, Dominique Goedhals, 
Armand Bester, Soo-Yon Rhee, Michele Tang, Tobias F Rinke de Wit, Katherine Brooks, Henry Sunpath, Avelin Aghokeng, Simon 
Agolory and James M Juma. 
 
ACTIONPlus Up: Charles Mensah, Patrick Dakum. Supported by The President’s Emergency Plan for AIDS Relief through 
cooperative agreement (5U2GGH000925-03) from HHS/Centers for Disease Control and Prevention (CDC), Global AIDS Program. 
AMPATH: We thank the study participants and AMPATH community, as well as Katherine Brooks, Allison DeLong, Maya 
Balamane, Marissa Reitsma, Emmanuel Kemboi, Millicent Orido, Mia Coetzer and Joseph Hogan for their help with patient 
enrollment, data generation and analyses in the original study.  
The findings and conclusions in this article are those of the authors and do not necessarily represent the official position of the U.S. 
Centers for Disease Control and Prevention. Use of trade names is for identification purposes only and does not constitute 
endorsement by the U.S. Centers for Disease Control. 
 
The Africa Centre drug resistance cohort was funded European Union (SANTE 2007 147–790), the US Centre for Diseases Control 
via CAPRISA (project title: Health Systems Strengthening and HIV Treatment Failure (HIV-TFC)) The data curation and research in 
this cohort was funded through a Medical Research Council flagship grant from the Republic of South Africa (MRC-RFA-UFSP-01-
2013/UKZN HIVEPI) and by a Royal Society Newton Advanced Fellowship to T.d.O.  
 
 
 
